Acyl-CoA:Cholesterol Acyltransferase

Acyl-coenzyme A (CoA):cholesterol acyltransferases (ACATs), EC 2.3.1.38, are integral membrane proteins that catalyze the conversion of cholesterol to cholesteryl esters. ACATs have been implicated in the pathology of atherosclerosis and Alzheimer's disease.

Products
Background
Literature
Gene Data

Inhibitors

Cat No Product Name / Activity
2227 CI 976
Selective ACAT inhibitor
2988 VULM 1457
ACAT inhibitor
3039 YM 750
ACAT inhibitor

Acyl-coenzyme (CoA):cholesterol acyltransferases (ACATs), EC 2.3.1.38, are integral membrane proteins that belong to the membrane bound O-acyl transferase (MBOAT) family. Two ACAT isoforms have been identified to date, ACAT1 and ACAT2, both of which are important for cholesterol homeostasis in normal tissues.

ACATs are expressed at low levels in the membrane of the endoplasmic reticulum. ACAT1 has almost ubiquitous tissue expression, being expressed in macrophages, liver hepatocytes and neurons, amongst others. In contrast ACAT2 has a more limited expression profile, although it is also expressed in macrophages and hepatocytes, albeit at lower levels. ACATs catalyze the conversion of excess cholesterol to cholesteryl esters (CEs). Cholesterol itself determines the activity of ACAT1, with increases and reductions in cholesterol levels resulting in enhanced or suppressed ACAT1 activity, respectively. Certain factors can also regulate ACAT1 gene expression, for example interferon-γ, urotensin-II and dexamethasone enhance ACAT1 expression, whereas ACAT1 is downregulated by adiponectin.

The upregulation of ACAT1 expression and the chronic accumulation of CE is associated with the formation of foamy macrophages and the onset and progression of atherosclerosis. Therefore the ACATs have been identified as a potential antiatherosclerotic therapeutic target. Inhibition of ACAT has been shown to reduce atherosclerotic plaque CE content and cause plaque regression in vivo. Furthermore ACAT could be a potential target for the treatment of Alzheimer's disease (AD). ACAT inhibition reduced amyloid plaque density in a mouse model of AD, although the exact mechanism is yet to be determined.

External sources of pharmacological information for Acyl-CoA:Cholesterol Acyltransferase :

    Literature for Acyl-CoA:Cholesterol Acyltransferase

    Cardiovascular

    Cardiovascular Research Product Guide

    A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

    • Hypertension
    • Thrombosis and Hemostasis
    • Atherosclerosis
    • Myocardial Infarction
    • Ischemia/Reperfusion Injury
    • Arrhythmias
    • Heart Failure
    Alzheimer's

    Alzheimer's Poster

    Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

    Acyl-CoA:Cholesterol Acyltransferase Gene Data

    Gene Species Gene Symbol Gene Accession No. Protein Accession No.
    ACAT1 Human ACAT1 NM_000019 P24752
    Mouse Acat1 NM_144784 Q8QZT1
    Rat Acat1 NM_017075 NP_058771
    ACAT2 Human ACAT2 NM_005891 Q9BWD1
    Mouse Acat2 NM_009338 Q8CAY6
    Rat Acat2 NM_001006995 Q5XI22